Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Patiënten doorverwezen naar de Chronische Pijn Eenheid voor palliatieve behandeling met ozontherapie tussen 2026 en 2029. (EPOOzo-2)

22 september 2026 bijgewerkt door: Bernardino Clavo, MD, PhD

Prospectief en Observationeel Onderzoek van Patiënten Verwezen naar de Chronische Pijn Eenheid voor Palliatieve Behandeling met Ozonetherapie Tussen 2026 en 2029. Prospectieve Studie EPOOzo-2.

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.

Studie Overzicht

Gedetailleerde beschrijving

Patients are referred to the Chronic Pain Unit in the absence or failure of standard treatment, or when the standard treatment is associated with high morbidity or high risk. Frequently, these patients present alterations in self-perceived health-related quality of life (HRQoL), anxiety, depression, and other symptoms such as radiation-induced pelvic toxicity or chemotherapy-induced peripheral neuropathy (CIPN).

This prospective observational study (EPOOzo-2) aims to evaluate the effect of adjuvant symptomatic/palliative ozone therapy on HRQoL and potential changes from baseline. Specifically, it incorporates new non-invasive technologies to objectively assess microcirculation, neuropathy and autonomic regulation.

Main Objectives:

1. Analyze the impact on HRQoL of patients with refractory symptoms treated with ozone.

Secondary Objectives: Depending on the clinical case, analyze the impact of ozone treatment on: 2. Anxiety and depression. 3. Treated symptoms (e.g., pain, paresthesia). 4. Fatigue. 5. Toxicity grade (in cancer patients). 6. Non-invasive clinical parameters related to the Autonomic Nervous System (central and peripheral) and somatosensory function. 7. Biochemical parameters and gut microbiome analysis (in patients with systemic/rectal ozone).

Methodology: Prospective and observational study of patients referred for symptomatic/palliative ozone therapy between January 2026 and December 2029.

Assessments at weeks: 0 (baseline), 16 (end of O3/O2 treatment), 28 (12 weeks after the end of ozone), and 40 (24 weeks after the end of ozone).

Studietype

Observationeel

Inschrijving (Geschat)

120

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Francisco Rodríguez-Esparragón, BSc, PhyD
  • Telefoonnummer: +34 928449288
  • E-mail: afrodesp@gmail.com

Studie Locaties

    • Las Palmas
      • Las Palmas de Gran Canaria, Las Palmas, Spanje, 35019
        • Werving
        • Dr. Negrín University Hospital
        • Contact:
          • Francisco Rodríguez-Esparragón, BSc, PhyD
          • Telefoonnummer: +34 928449288
          • E-mail: afrodesp@gmail.com
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín, between January 2026 and December 2029, for symptomatic/palliative treatment with ozone therapy because standard treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.

Beschrijving

Inclusion Criteria:

  • 1. Adults ≥ 18 years old.
  • 2. Patients referred to the Chronic Pain Unit of the Dr. Negrín University Hospital for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, has failed, has offered insufficient results, or is associated with high risk/morbidity.
  • 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.
  • 4. Patients have no contraindications for ozone treatment.
  • 5. Patients must sign the specific Informed Consent for this study and for the ozone treatment.

Exclusion Criteria:

  • 1. Age < 18 years old.
  • 2. Psychiatric illness or social situations that would limit compliance with study requirements.

Contraindication or disability to attend scheduled treatments.

  • 3. Contraindication or disability to attend scheduled treatments.
  • 4. Uncontrolled clinical conditions (e.g., severe heart failure, massive hemorrhage, status epilepticus).
  • 5. Life expectancy < 6 months.
  • 6. Known allergy to ozone.
  • 7. Hemochromatosis (for systemic ozone treatment).
  • 8. Pregnancy (for systemic ozone treatment).
  • 9. Significant Glucose-6-Phosphate Dehydrogenase deficiency (Favism) (for systemic ozone treatment).
  • 10. Patients who do not meet the inclusion criteria.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: CASE_ONLY
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Ozone Group

Patients with refractory symptoms referred for palliative treatment with ozone therapy between 2026 and 2029.

Systemic (rectal, autohemotherapy) and/or local ozone administration (cutaneous, intravaginal, intravesical). Dosage, frequency, and duration will depend on the symptoms treated and clinical evolution. Usually planned 40 sessions over 4 months.

Andere namen:
  • Ozonbehandeling

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At the end of ozone therapy (approx. week 16).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 24 weeks after the end of ozone therapy).
Tijdsspanne: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 week after the end of ozone therapy (approx. week 28).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 12 week after the end of ozone therapy (approx. week 28).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 24 weeks after the end of ozone therapy).
Tijdsspanne: At 24 week after the end of ozone therapy (approx. week 40).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 24 week after the end of ozone therapy (approx. week 40).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At the end of ozone therapy (approx. week 16).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 24 weeks after the end of ozone therapy).
Tijdsspanne: At 24 weeks after the end of ozone therapy (approx. week 40).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At the end of ozone therapy (approx. week 16).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 24 weeks after the end of ozone therapy).
Tijdsspanne: At 24 weeks after the end of ozone therapy (approx. week 40).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Pain Score (Visual Analog Scale), (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At the end of ozone therapy (approx. week 16).
Change from Baseline in Pain Score (Visual Analog Scale), (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Pain Score (Visual Analog Scale), (at 24 weeks after the end of ozone therapy).
Tijdsspanne: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At the end of ozone therapy (approx. week 16).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 24 weeks after the end of ozone therapy).
Tijdsspanne: At 24 weeks after the end of ozone therapy (approx. week 40).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Postural Stability (Equilibrium Platform), (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Postural Stability (Equilibrium Platform), (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Heart Rate Variability (HRV), (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Heart Rate Variability (HRV), (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At the end of ozone therapy (approx. week 16).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At the end of ozone therapy (approx. week 16).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Gut Microbiota Composition (at the end of ozone therapy).
Tijdsspanne: At the end of ozone therapy (approx. week 16).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Gut Microbiota Composition (at 12 weeks after the end of ozone therapy).
Tijdsspanne: At 12 weeks after the end of ozone therapy (approx. week 28).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At 12 weeks after the end of ozone therapy (approx. week 28).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
  • Hoofdonderzoeker: Francisco Rodríguez-Esparragón, BSc, PhyD, Dr. Negrín University Hospital, Las Palmas, Spain
  • Hoofdonderzoeker: Ángeles Cánovas-Molina, RN, Dr. Negrín University Hospital, Las Palmas, Spain

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

14 januari 2026

Primaire voltooiing (Geschat)

31 december 2029

Studie voltooiing (Geschat)

30 juni 2030

Studieregistratiedata

Eerst ingediend

23 december 2025

Eerst ingediend dat voldeed aan de QC-criteria

23 december 2025

Eerst geplaatst (Werkelijk)

8 januari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

23 september 2026

Laatste update ingediend die voldeed aan QC-criteria

22 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

  • It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
  • Data will be available after publication, ending 36 months following the article publication.
  • They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

IPD-tijdsbestek voor delen

Data will be available after publication, ending 36 months following article publication.

IPD-toegangscriteria voor delen

They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren